A promising new medicine can spend years moving through laboratories, clinical trials and regulatory review before it ever reaches a patient. Artificial intelligence is now being used to attack many of the delays surrounding that process, from searching scientific literature and designing drug candidates to organizing clinical trials and improving manufacturing. But there is an important distinction: AI cannot simply make a patient’s biological response happen faster. Its biggest opportunity may be to remove the administrative, computational and logistical bottlenecks that surround the science. That could change how quickly medicines move from an idea in a laboratory to a treatment people can actually receive.
Finding A New Drug Has Always Been A Slow Process
Developing a medicine begins with a difficult search. Researchers must identify a biological target, determine how that target is linked to disease and then search through an enormous chemical space for molecules that might interact with it safely and effectively.
Historically, much of this work required scientists to move through the evidence step by step, searching scientific papers, databases, experimental results and internal records before deciding what to test next. The amount of information has grown so quickly that simply finding and organizing relevant evidence can consume enormous amounts of research time. Genentech says its scientists have been using AI tools to integrate information from large datasets and accelerate target identification and drug design.
The change is not that computers have suddenly replaced laboratory science. It is that machines can now perform some of the information-heavy parts of the process at a scale that would be extremely difficult for a human research team to match. That is where the first major time savings can appear.
Discover how NVIDIA and Eli Lilly are revolutionizing drug discovery! Witness the power of AI-driven supercomputing and digital twin technology reshaping the future of medicine. From tackling obesity to mapping the aging brain, see how this groundbreaking partnership is turning complex biology into an engineering problem. Watch now for more!
AI Can Search Millions Of Possibilities At Once
One of the clearest examples comes from Genentech’s research operation.
The company has built an AI research agent that can search roughly 38 million biomedical publications to help identify drug targets and validate biomarkers. Genentech estimates that the system could automate more than 43,000 hours of manual biomarker-validation work each year across therapeutic areas.
AI can also help propose candidate molecules, predict their properties and use the results of one experiment to influence what should be tested next. Instead of researchers treating every experiment as an isolated step, computational systems can help create a continuous loop: predict, test, learn and select the next experiment.
The potential advantage is enormous because drug discovery involves an almost unfathomably large number of possible molecules and biological interactions. But speed alone does not make a drug successful. A computer can suggest a promising molecule. Only experiments can show whether it behaves as predicted.
Clinical Trials Have A Different Bottleneck
Once a drug candidate is ready for human testing, the problem changes.
Clinical trials require patients, doctors, research sites, data systems, regulatory documents and constant coordination among organizations that may be spread across different cities or countries. Some of that work is scientific, but a great deal of it is administrative. That distinction is becoming an important target for AI.
USA TODAY reported that AI companies working with pharmaceutical and clinical-research organizations are using AI agents to support study start-up, document management, regulatory work, site management and data queries. One example described work that had originally been expected to take about six months being completed in less than eight weeks—not because patients were monitored for less time, but because the administrative work surrounding the trial was completed faster. That difference matters.
AI is not supposed to make a biological trial “finish” before enough data has been collected. It can, however, reduce the time spent waiting for documents, resolving repetitive requests, preparing records or moving information between systems. In other words, the machine may not shorten the experiment itself. It can shorten the amount of time humans spend getting the experiment ready.
AI Is Beginning To Operate Across The Whole Drug Pipeline
The most ambitious pharmaceutical companies are no longer treating AI as one specialized tool.
Genentech describes an end-to-end approach that covers target identification, molecule design, clinical-trial planning and manufacturing. The company is also developing “lab-in-the-loop” systems in which AI predictions are connected to physical experiments, allowing new experimental results to feed back into the next round of computational recommendations.
The idea is important because drug development is not a straight line.
A discovery made in the laboratory can affect clinical-trial design. Trial results can change how researchers think about a drug target. Manufacturing problems can force changes to a formulation or process. A system that connects those stages could reduce the delays created when information becomes trapped inside separate departments.
That vision is now being tested at a much larger scale.
In September 2026, Stanford researchers described a “Virtual Biotech” built from as many as 37,000 AI agents. The system was structured like a pharmaceutical company, with specialized AI agents handling tasks such as target identification, clinical-trial analysis and therapeutic strategy. In one demonstration, the agents analyzed outcomes from more than 55,000 clinical trials to look for patterns associated with successful drug development.
That is a research demonstration rather than a replacement for a real pharmaceutical company, but the scale shows where the technology is heading.
Digital Twins Could Speed Up Manufacturing Too
The final challenge is making enough of a medicine once it has been developed.
A drug can succeed scientifically and still encounter manufacturing problems involving equipment, production schedules, quality control or the movement of materials. Pharmaceutical companies are therefore exploring AI beyond the discovery laboratory.
Genentech says it is building digital twins of manufacturing plants that model the movement of materials, processes and personnel. These virtual environments can be used to test changes and optimize operations before making the same changes in a physical facility.
This could matter because manufacturing is another place where a small bottleneck can delay a medicine long after the underlying scientific discovery has already been made.
The broader goal is becoming clear: use computers to find problems earlier, test more possibilities and coordinate complicated systems faster. The medicine still has to be physically produced.
But the decisions surrounding that production can increasingly be simulated before the factory floor has to change.
The Fastest Part Of Drug Development May Not Be The Most Important
There is a temptation to assume that AI will turn drug development from a years-long process into a matter of months. That is not what the evidence currently shows.
Some parts of the process can already move dramatically faster. AI can search enormous amounts of information, generate hypotheses, analyze historical trial data and automate repetitive research tasks. The FDA is also pursuing programs designed to accelerate clinical development, including a 2026 pilot intended to reduce the time between identifying a drug and beginning a first-in-human trial. But the central biological questions remain.
Does the drug actually work? Is it safe? What dose should a patient receive? How does the treatment behave across different populations? Those questions still require evidence from experiments and clinical studies. Regulators cannot simply accept an AI prediction as proof that a medicine is effective. That is why the most realistic near-term story is not “AI replaces drug development.”
It is “AI removes some of the waiting around drug development.” That may sound less dramatic, but it could be extremely important.
If scientists can spend less time searching through documents, designing routine analyses and managing repetitive administrative work, they can devote more time to experiments and decisions that require human judgment. If clinical-trial operations can move faster without reducing the quality of the evidence, promising treatments may enter trials sooner. If manufacturing problems can be predicted earlier, successful medicines may reach production more smoothly. The ultimate goal is not to make every step instant. It is to make fewer steps unnecessarily slow.
And that could change the journey of a medicine in a way patients may eventually notice—not because AI eliminated the need for science, but because it helped scientists spend more of their time doing the part that only science can do.
AI is unlikely to turn drug development into an instant process, but it is already changing how quickly some of the work around medicine can be done. Algorithms can search millions of scientific records, generate drug candidates, analyze trial data, automate administrative tasks and model manufacturing systems. The biology still has to be tested in the real world, and safety and effectiveness still require evidence. The biggest change may therefore be less dramatic than “AI invents drugs overnight”: machines are beginning to remove some of the delays that have surrounded drug development for decades.
The original USA TODAY report examines how AI is being used across different stages of medicine development, from discovering drug candidates to organizing clinical trials and improving research operations. Recent work from Genentech, Stanford researchers and the FDA shows how quickly these applications are expanding from individual tools into broader drug-development systems. Source: https://www.usatoday.com/story/money/money-management/healthcare/2026/09/04/ai-new-medicines-faster/91565550007/
